INAB READ THE FULL INAB RESEARCH REPORT Following the announcement of its new γδ T cell engager platform INB-600, IN8bio, Inc ...
A T-cell therapy developed by Orca Bio, a private biotech company, significantly reduced the risk of a debilitating immune ...
In a late-stage trial of patients with multiple types of blood cancer, Orca Bio’s allogeneic T-cell immunotherapy doubled the ...
Orca-T improved 1-year survival without severe graft-vs-host disease compared with standard transplant in the Precision-T ...
2don MSNOpinion
My survival is based on research. With limited NIH funding, I fear that my life, and the lives of others, will be left ...
Results showed Orca’s treatment, a purified mix of donor-derived T cells and stem cells, was safer than standard transplant ...
The Brighterside of News on MSN5d
New CAR-T therapy achieved complete remission in 70% of aggressive cancer patientsCAR-T cell therapy has revolutionized the treatment of relapsed and refractory B-acute lymphoblastic leukemia (B-ALL), with ...
From STAT’s Andrew Joseph: AstraZeneca said this morning it was buying the Belgian cell therapy company EsoBiotec for $425 ...
Interesting Engineering on MSN7d
US researchers develop next-gen CAR-T therapy to kill hard-to-treat cancersCART, a next-gen CAR-T therapy for improved targeting and functionality to address this. “ALA-CART improves the ability of ...
Researchers uncover how leukemia drains T cells' energy, paving the way for stronger cancer immunotherapy and enhancing CAR T ...
Chromosomal Chaos Promotes Therapy Resistance in Leukemia Cells and Opens Up New ... Promising Cell Therapy Offers Hope for Relapsed or Refractory T-Cell Leukaemia Oct. 7, 2024 — Fratricide ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback